论文部分内容阅读
应用ＪＳＢ－１单克隆抗体（单抗），采用间接免疫荧光法对１０３例初诊急性髓细胞白血病（ＡＭＬ）患者ｍｄｒ１基因表达产物ｐ－１７０进行检测，发现ｐ－１７０表达率为２６％；ＡＭＬ亚型中以Ｍ＿５的ｐ－１７０表达率最高；ｐ－１７０表达与化疗反应及预后高度相关。同时应用一组相关单抗，采用同样方法分析了其中６７例患者细胞免疫标记与ｐ－１７０表达及预后的关系。结果显示：ＣＤ＿（１４）或ＣＤ＿（３４）表达与ｐ－１７０表达及预后高度相关；ＣＤ＿（１４）或ＣＤ＿（３４）与ｐ－１７０协同表达者更难获得ＣＲ，预后更差。提示在进行ｐ－１７０表达检测的同时，观察相关免疫标记的表达情况并进行综合分析，可能对预测化疗疗效及判断预后更有意义。
The mdr1 gene expression product p-170 in 103 newly diagnosed acute myeloid leukemia (AML) patients was detected by indirect immunofluorescence with JSB-1 monoclonal antibody (mAb). The expression rate of p-170 was 26%. AML Subtypes M_5 p-170 highest expression rate; p-170 expression and chemotherapy response and prognosis are highly related. At the same time, a group of related monoclonal antibodies were used in the same way to analyze the relationship between the cellular immune markers and the expression and prognosis of p-170 in 67 patients. The results showed that the expression of CD_ (14) or CD_ (34) was highly correlated with the expression and prognosis of p-170. The CD_ (14) or CD_ (34) and p-170 co-expression were more difficult to obtain CR with poorer prognosis. It is suggested that it is more meaningful to predict the curative effect of chemotherapy and to predict the prognosis while observing the expression of related immune markers and carrying out comprehensive analysis while carrying out the detection of p-170 expression.